Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats ...

Shionogi & Co. has been awarded a $375 million project agreement by the Biomedical Advanced Research and Development ...

PopVax awarded $2M for its patch-delivered mRNA influenza vaccine in collaboration with LTS Lohmann as part of BARDA’s Patch Forward Prize.

Moderna MRNA announced that the U.S. government, through the Biomedical Advanced Research and Development Authority (“BARDA”), has awarded the company $590 million to accelerate the ...

Established in 2006, the mission of the BARDA is to develop and procure medical countermeasures, vaccines, drugs, therapeutics, diagnostic tools, and nonpharmaceutical products, that address the ...

Vaxxas Named Stage Winner of United States’ BARDA Prize to Advance Microarray Patches for Vaccination ...

Bioxytran presented four key Areas of Interest (AOI): an influenza antiviral, immune modulators for lung repair, solutions for uncontrolled hemorrhaging, and a versatile strategic therapeutic. The ...

The United States Biomedical Advanced Research and Development Authority (BARDA) has announced Vaxxas will receive US$2 million (AU$3.2 million) as a Concept Stage Winner in its multi-stage $50 ...